semaglutide company Ivím Health Obesity | Novo Nordisk U.S.

The PlexusDx Precision Peptide Genetic Test identifies variants affecting GLP-1 receptor sensitivity and metabolic pathways, allowing clinicians to personalize your semaglutide dose and potentially switch to tirzepatide or GLP-Squared if your genetic profile suggests superior outcomes with dual-compound therapy

In the retatrutide phase 2 trial, nausea rates at the 12 mg dose reached 45.4% [2]

Used with full medical evaluation to personalize care

This paper discusses these factors in comprehensive detail while offering solutions to ensure a superior product experience

Semaglutide GLP-1, a medication increasingly being used in the weight management field, is one of the options our healthcare professionals may recommend